Cover Image
市場調查報告書

miRNA研究、診斷市場

miRNA Research and Diagnostics Markets

出版商 Kalorama Information 商品編碼 316321
出版日期 內容資訊 英文 200 Pages
訂單完成後即時交付
價格
Back to Top
miRNA研究、診斷市場 miRNA Research and Diagnostics Markets
出版日期: 2014年09月04日 內容資訊: 英文 200 Pages
簡介

本報告特別以微型核糖核酸為重點,提供對非編碼RNA分子診斷的潛力相關調查、miRNA概要、miRNA診斷技術的正面要素和負面要素、理論上的限制、專利問題相關討論、主要企業簡介及市場規模預測等彙整資料。

第1章 摘要整理

第2章 簡介

  • 無用DNA:是否有這種東西?
  • 充滿了活力的議論
  • RNA分子控制基因表現
  • 非編碼RNA的種類
  • 小型RNA的種類

第3章 目前最新情形

  • 改善診斷的改變遊戲規則者
  • 微型核糖核酸的命名次序
  • 微型核糖核酸的生源
  • 微型核糖核酸的細胞功能
  • 微型核糖核酸及其他疾病
  • 治療用途的探討

第4章 微型核糖核酸診斷技術的開發企業

  • Agilent Technologies
  • Alnylam
  • AMSBIO
  • Applied Biosystems
  • Asuragen
  • DiamiR, LLC
  • Dicerna
  • Eisai Biomarkers and Personalized Medicine
  • Diagnostics
  • Exiqon
  • Genomic Health Inc.
  • Gensignia
  • GlaxoSmithKline Discovery and Molecular Toxicology
  • Groove Biopharma (formerly Mirina)
  • Hologic-Gen Probe Inc.
  • Illumina, Inc.
  • Isis Pharmaceuticals
  • Mello Biotechnology Inc.
  • Microlin Bio
  • MiRagen Therapeutics
  • MiRNA Therapeutics
  • Novartis
  • Pacific Edge Biotechnology
  • Prolias Technologies
  • Regulus Therapeutics
  • Rosetta Genomics
  • Santaris Pharma A/S
  • Sirnaomics, Inc.
  • Somagenics
  • Diagnostics: Small RNA Assays and Biomarker Validation
  • Tekmira Pharmaceuticals Corporation
  • Thermadiag
  • Thermo Fisher Scientific, Inc.

第5章 市場估計與預測

  • 長期性的估計
  • 可能帶給miRNA診斷技術展望負面影響的要素
  • 推翻估計的正面要素

第6章 專家採訪:生物標記

第7章 miRNA型診斷的未來

  • 未來預測
  • 建議的摘要

圖表清單

目錄
Product Code: KLI5332151

This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that do not produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, a large number of companies, both small biotechs and big pharmaceutical companies are committed to miRNA diagnostics.

As part of its coverage of this topic, this report includes the following:

  • Overview of miRNAs
  • Positive Factors for miRNA Diagnostic Technologies
  • Negative Factors
  • miRNAs and Neurological Disorders
  • miRNA and Metastatic Brain Lesions
  • Prostate Cancer Screening and miRNAs
  • miRNAs and Resistance to Anti-Cancer Drugs
  • Theoretical Limitations
  • Discussion of Patent Issues
  • Interviews with Industry Experts
  • Market Estimate

One the positive side of the equation, the technology is innovative, and offers the promise of non-invasive diagnostics for cancer and other disorders that could be cheaper, faster and more accurate than existing tests, which are either non-existent or leave much to be desired. On the negative side of the equation, there are many complex challenges that must be resolved before the technology can be applicable. There is a need for large scale clinical trials, and rigorous standardization of the assay conditions, given the fact that the assessments of serum levels of miRNA molecules are quantitative. This report considers the potential for the miRNA market in research and diagnostics and the challenges. In doing so, the report looks at several companies currently developing research and diagnostic miRNA technologies.

As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail.

  • Agilent Technologies
  • Alnylam
  • AMSBIO
  • Applied Biosystems
  • Asuragen
  • DiamiR, LLC
  • Dicerna
  • Eisai Biomarkers and Personalized Medicine
  • Diagnostics
  • Exiqon
  • Genomic Health Inc.
  • Gensignia
  • GlaxoSmithKline Discovery and Molecular Toxicology
  • Groove Biopharma (formerly Mirina)
  • Hologic-Gen Probe Inc.
  • Illumina, Inc.
  • Isis Pharmaceuticals
  • Mello Biotechnology Inc.
  • Microlin Bio
  • MiRagen Therapeutics
  • MiRNA Therapeutics
  • Novartis
  • Pacific Edge Biotechnology
  • Prolias Technologies
  • Regulus Therapeutics
  • Rosetta Genomics
  • Santaris Pharma A/S
  • Sirnaomics, Inc.
  • Somagenics
  • Diagnostics: Small RNA Assays and Biomarker Validation
  • Tekmira Pharmaceuticals Corporation
  • Thermadiag
  • Thermo Fisher Scientific, Inc.

Table of Contents

1. Executive Summary

2. Introduction

  • 2.1. Junk DNA: Is There Such a Thing
  • 2.2. An Animated Debate
  • 2.3. RNA Molecules Regulate Gene Expression
  • 2.4. Types of Non-coding RNAs
  • 2.5. Types of Small RNAs

3. Current State of the Art

  • 3.1. A Game Changer for Improved Diagnosis
    • 3.1.1. MicroRNAs Are a Factor in Many Diseases
    • 3.1.2. miRNAs and Neurological Disorders
    • 3.1.3. miRNA and Metastatic Brain Lesions
    • 3.1.4. miRNA Involvement in Cancers Is Widespread
    • 3.1.5. Prostate Cancer Screening and miRNAs
    • 3.1.6. Bladder Cancer and MicroRNAs in Urine
    • 3.1.7. Colorectal Cancer
    • 3.1.8. miRNAs and Resistance to Anti-Cancer Drugs
  • 3.2. MicroRNA Nomenclature
  • 3.3. MicroRNA Biogenesis
  • 3.4. MicroRNA Cellular Functions
  • 3.5. MicroRNA and Other Diseases
    • 3.5.1. How Are microRNAs Linked to Disease
    • 3.5.2. Circulating microRNAs as Disease Markers
    • 3.5.3. miRNAs and Tissue Injury
    • 3.5.4. The Exosome
  • 3.6. Exploring Therapeutic Applications
    • 3.6.1. A Cautionary Tale: The History of Antibody Development
    • 3.6.2. A Mixed Assessment of miRNA Therapeutic Potential

4. Companies Developing microRNA Diagnostic Technologies

  • 4.1. Agilent Technologies
  • 4.2. Alnylam
  • 4.3. AMSBIO
  • 4.4. Applied Biosystems
  • 4.5. Asuragen
  • 4.6. DiamiR, LLC
  • 4.7. Dicerna
  • 4.8. Eisai Biomarkers and Personalized Medicine
  • 4.9. Diagnostics
  • 4.10. Exiqon
  • 4.11. Genomic Health Inc.
  • 4.12 Gensignia
  • 4.13. GlaxoSmithKline Discovery and Molecular Toxicology
  • 4.14. Groove Biopharma (formerly Mirina)
  • 4.15. Hologic-Gen Probe Inc.
  • 4.16. Illumina, Inc.
  • 4.17. Isis Pharmaceuticals
  • 4.18. Luminex (Millipore)
  • 4.19. Mello Biotechnology Inc.
  • 4.20. Microlin Bio
  • 4.21. MiRagen Therapeutics
  • 4.22. MiRNA Therapeutics
  • 4.23. Novartis
  • 4.24. Pacific Edge Biotechnology
  • 4.25. Prolias Technologies
  • 4.26 Regulus Therapeutics
    • 4.26.1. Biomarker Studies of miRNAs through the Application of Microarrays
    • 4.26.2. Clinical Trials
  • 4.27. Rosetta Genomics
  • 4.28. Santaris Pharma A/S
  • 4.29. Sirnaomics, Inc.
  • 4.30. Somagenics
    • 4.30.1. Diagnostics: Small RNA Assays and Biomarker Validation
  • 4.31. Tekmira Pharmaceuticals Corporation
  • 4.32. Thermadiag
  • 4.33. Thermo Fisher Scientific, Inc.

5. Market Estimates and Forecasts

  • 5.1. Long Range Estimate
  • 5.2. Negative Forces That Can Affect the Outlook for miRNA Diagnostic Technologies
    • 5.2.1. Theoretical Limitations of miRNAs
    • 5.2.2. Resistance to miRNA R&D on the Part of Big Pharma
    • 5.2.3. Lack of Basic Science Support by Government Funding Agencies
    • 5.2.4. Patent Issues
  • 5.3. Positive Factors That Move the Estimates
    • 5.3.1. Inherent Shortcomings of Competitive Detection Systems
    • 5.3.2. miRNA Technological Improvements
    • 5.3.3. Current Studies Are Encouraging
    • 5.3.4. Availability of Venture Capital
    • 5.3.5. Specific Venture Capital Funding Opportunities

6. Interviews with Industry Experts: Biomarkers

  • 6.1. Anton Wellstein MD, PhD
  • 6.2. Kai Wang, PhD
  • 6.3. Samuil R. Umansky, MD, PhD
  • 6.4. Dr. Mustafa Ozen
  • 6.5. Dr. Nader Rifai

7. The Future of miRNA-Based Diagnostics

  • 7.1. Future Perspectives
  • 7.2. Summary Recommendations
    • 7.2.1. MicroRNA Compares Well with Competing Technologies
    • 7.2.2. MicroRNA Assessment, Based on Its Own Performance
    • 7.2.3. A Nuanced Endorsement

LIST OF EXHIBITS

1. Executive Summary

  • Table 1.1: Forms of RNA and Abbreviations Explained

2. Introduction

  • Table 2.1: Different Classes of RNA Molecules

3. Current State of the Art

  • Figure 3.1: Increasing Number of Publications on miRNA
  • Figure 3.2: Results of microRNA Microarray Analysis
  • Table 3.1: Colorectal Cancer-Associated miRNA Markers
  • Figure 3.3: Method Validation: miRNAs Associated with Prostate Cancer
  • Table 3.2: Verification of Known Tissue-Specific Expression Patterns of Three mRNAs as Markers of Tissue Injury (miR-122, miR-133a and miR-124 Concentrations in Nine Rat Tissues)
  • Figure 3.4: Exosomes
  • Figure 3.5: Lagging Rate of Therapeutic Antibody Approval

4. Companies Developing microRNA Diagnostic Technologies

  • Figure 4.1: Biogenesis of microRNAs (Gensignia)
  • Table 4.1: Regulus' Clinical Map Initiative Outlines Current Status of Its microRNA Therapeutics Pipeline
  • Figure 4.2: Natural microRNA Precursors Marketed by Mello Biotech
  • Table 4.2: Summary of Data from Regulus miRNA Assessment Study

5. Market Estimates and Forecasts

  • Table 5.1: miRNA Testing Market
  • Table 5.2: Major Providers of miRNA Tools and Services
  • Table 5.3: Top 10 Pharmaceutical Companies by R&D Expenditures in 2013
  • Figure 5.1: Funding Trends for Basic Research, 1950-2019
  • Table 5.4: Some Venture Capital Funding Opportunities
Back to Top